Editing Nextera

{{DISPLAYTITLE:Nextera}}
{{Infobox company
| name = Nextera AS
| org_number = 994486594
| founded = 2009-08-12
| employees = 9
| address = Oslo Innovation Centre, Gaustadalleen 21, 0349 Oslo
| industry = 72.100 – Biotechnology research
| website = https://www.nextera.no
| nht_category = Startup
| description = Nextera is a drug and target discovery company spun out from University of Oslo and Oslo University Hospital. Developing NextCore platform (pIX phage display) for TCR-Like antibodies targeting pHLA antigens in cancer and autoimmunity. Pipeline includes TCR-Like antibody lead candidates. Received Norwegian Research Council IPN funding November 2025. CEO/CSO Geir Aage Loset. Active at PEGS Europe 2025.
| notes = 9 employees. NRC funding confirmed Nov 2025. Most commercially active biotech in this batch. Presence at PEGS Europe 2025 indicates international visibility.
| related_companies = [[Hemispherian]], [[Exact Therapeutics]], [[Pharmasum Therapeutics]], [[Nordic Brain Tech]], [[Norway Health Tech]]
| categories = Norway Health Tech, Startups, Biotechnology, Drug Discovery, Oncology, Immunology
| sources = https://www.nextera.no; https://data.brreg.no/enhetsregisteret/api/enheter/994486594
}}

== About ==

Nextera AS is a Norwegian drug discovery and target discovery company spun out from a Centre of Excellence research environment at the University of Oslo and Oslo University Hospital. The company was founded in 2009.

== Technology ==

=== NextCore Platform ===

Nextera's proprietary discovery platform combines deep insight into disease mechanisms with unique technology innovation. The platform integrates:

* '''NextCore''' — an integrated platform for developing precision drug candidates targeting the intracellular universe of disease antigens through pHLA (peptide-HLA)
* '''pIX phage display technology''' — core technology enabling discovery of novel antibody candidates

== Pipeline ==

The company is developing a pipeline of TCR-Like antibody lead candidates with:
* Exquisite specificity toward disease-specific pHLA targets
* Unique potency for targeted immunotherapy
* Applications in cancer and autoimmunity

== Recent Activity ==

* November 2025: Received funding from the Norwegian Research Council through the Innovation Project for the Industrial Sector (IPN) for development of TCR-Like antibodies in autoimmune diseases
* November 2025: Presentation at PEGS Europe 2025 in Lisbon (premier annual protein engineering conference)
* CEO/CSO Geir Aage Loset chairs sessions at PEGS Europe

== Strategy ==

Nextera's strategy is to discover new targets and develop cognate drugs together with partners, addressing complex diseases in major indications that are currently difficult to treat.

== References ==
<references/>

[[Category:Norway Health Tech]]
[[Category:Startups]]
[[Category:Biotechnology]]
[[Category:Drug Discovery]]
[[Category:Oncology]]
[[Category:Immunology]]